Sangeetha Reddy, M.D.

Assistant Professor

School: Medical School
Department: Internal Medicine
Graduate Programs: Cancer Biology, Immunology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

Biography

Sangeetha Reddy, M.D., M.Sc., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology.

Originally from Baltimore, Dr. Reddy holds a bachelor's degree in biochemical sciences from Harvard University in Cambridge, Massachusetts. She earned her medical degree at the University of California Los Angeles Geffen School of Medicine. She completed internal medicine residency training at McGaw Medical Center of Northwestern University in Chicago, followed by a master's degree in clinical science. She then completed advanced training through a fellowship in medical hematology and oncology at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Reddy joined the UT Southwestern faculty in 2019. Dr. Reddy's clinical interests include metastatic disease, triple-negative breast cancer, inflammatory breast cancer, and pregnancy-associated breast cancer. Dr. Reddy has been selected as a Cancer Prevention and Research Institute of Texas Recruitment Award recipient and also a Disease-Oriented Clinical Scholar to support her breast cancer research efforts.

Education

Medical School: David Geffen School of Medicine at UCLA (2010)
Residency: McGaw Medical Center of Northwestern University (2013), Internal Medicine
Chief Resident: McGaw Medical Center of Northwestern University (2014), Internal Medicine
Fellowship: UT MD Anderson Cancer Center (2017), Hematology Oncology

Research Interest

Publications

Featured Publications

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.: Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N Cell 2018 Nov 175 4 998-1013.e20
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.: Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA Nat. Med. 2018 Nov 24 11 1649-1654
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.: Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, Hortobagyi GN, Valero V Br. J. Cancer 2018 01 118 1 17-23
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.: Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA Cancer Res. 2017 10 77 19 5374-5383
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.: Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA Sci Transl Med 2017 03 9 379
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.: Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA NPJ Genom Med 2017 2
Impact of Statin Use on Outcomes in Triple Negative Breast Cancer.: Shaitelman SF, Stauder MC, Allen P, Reddy S, Lakoski S, Atkinson B, Reddy J, Amaya D, Guerra W, Ueno N, Caudle A, Tereffe W, Woodward WA J Cancer 2017 8 11 2026-2032
Monitoring immune responses in the tumor microenvironment.: Wargo JA, Reddy SM, Reuben A, Sharma P Curr. Opin. Immunol. 2016 08 41 23-31
Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade.: Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, Petaccia De Macedo M, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA Cancer Discov 2016 Jun
Targeting angiogenesis in metastatic breast cancer.: Reddy S, Raffin M, Kaklamani V Oncologist 2012 17 8 1014-26